Abstract
Objectives
As a common pathological type of non-small-cell lung cancer (NSCLC), Lung squamous cell carcinoma (LUSC) with high mortality lacks a desired diagnostic indicator and therapeutic target. This study is aimed to reveal low expression of Alpha-Sarcoglycan (SGCA) promotes LUSC progression to provide a biomarker for LUSC diagnosis, prognosis evaluation and targeted therapy.
Methods
The Cancer Genome Atlas (TCGA) and 70 LUSC patients in clinic were collected to assessed the correlation between SGCA expression and patients clinical data; in vitro, we examined the proliferation, apoptosis, and invasion of human LUSC H520 cells with overexpressed SGCA by transfecting pc-SGCA plasmids, comparing with that of the Ctrl group; in vivo, LUSC subcutaneous tumorigenic mouse mode was constructed to further explore the role of SGCA in LUSC.
Results
The analysis results of TCGA data indicate SGCA was significant in the diagnosis of LUSC and negatively correlated with T stage; The analysis results of the clinical data analysis suggest SGCA was negatively correlated with T stage, clinical stage, CYFRA21-1 and creatinine ; in vitro experiments validated low expression of SGCA enhanced the proliferation, invasion and migration ability, inhibited the cells apoptosis; in vivo experiments showed LUSC subcutaneous tumorigenic mouse model overexpression of SGCA inhibited the mice tumor growth.
Conclusion
SGCA has diagnostic significance in LUSC. Low expression of SGCA promotes proliferation, migration, invasion, and is closely associated with LUSC progression, and SCGA is thus proposed as a potential prognostic factor and therapeutical target for LUSC.